Olympiad Research LP Takes Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Olympiad Research LP bought a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 17,401 shares of the medical technology company’s stock, valued at approximately $160,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ATEC. Polar Asset Management Partners Inc. lifted its stake in shares of Alphatec by 381.9% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 621,224 shares of the medical technology company’s stock valued at $3,454,000 after acquiring an additional 492,324 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Alphatec in the 3rd quarter valued at about $2,057,000. Congress Asset Management Co. raised its position in Alphatec by 235.4% during the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company’s stock valued at $3,993,000 after purchasing an additional 305,296 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after purchasing an additional 297,850 shares during the last quarter. Finally, State Street Corp raised its position in Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after purchasing an additional 287,350 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Down 0.5 %

Shares of NASDAQ:ATEC opened at $10.61 on Monday. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $15.69. The firm has a market capitalization of $1.50 billion, a P/E ratio of -8.29 and a beta of 1.43. The stock has a 50 day moving average price of $10.48 and a 200-day moving average price of $8.26. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Insider Buying and Selling

In related news, CEO Patrick Miles sold 6,687 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the sale, the chief executive officer now owns 5,501,715 shares in the company, valued at $66,020,580. This represents a 0.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Scott Lish sold 27,453 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 222,376 shares of company stock worth $2,557,148 in the last 90 days. Insiders own 22.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on ATEC. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Needham & Company LLC upped their price target on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.56.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.